| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5360817 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2013
(10 years ago) | |
| US5648379 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2014
(9 years ago) | |
| US6294572 | GLAXOSMITHKLINE | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec, 2014
(9 years ago) | |
Relenza is owned by Glaxosmithkline.
Relenza contains Zanamivir.
Relenza has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Relenza are:
- US5360817
- US5648379
- US6294572
Relenza was authorised for market use on 26 July, 1999.
Relenza is available in powder;inhalation dosage forms.
Relenza can be used as prophylaxis of influenza.
The generics of Relenza are possible to be released after 15 December, 2014.
Drugs and Companies using ZANAMIVIR ingredient
Market Authorisation Date: 26 July, 1999
Treatment: Prophylaxis of influenza
Dosage: POWDER;INHALATION
More Information on Dosage
RELENZA family patents
